C. Germa

发表

PI3K inhibitors as new cancer therapeutics: implications for clinical trial design

E. di Tomaso, P. Aimone, C. Massacesi, 2016, OncoTargets and therapy.

Ribociclib Bioavailability Is Not Affected by Gastric pH Changes or Food Intake: In Silico and Clinical Evaluations

C. Germa, K. Umehara, S. Dhuria, 2017, Clinical pharmacology and therapeutics.

Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastoma.

E. Raymond, G. Vassal, J. Armand, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer.

Sung-Bae Kim, J. Baselga, Bing-he Xu, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First line chemotherapy with gemcitabine in advanced non-small cell lung cancer elderly patients: a randomized phase II study of 3-week versus 4-week schedule.

E. Lemarié, D. Moro-Sibilot, E. Quoix, 2005, Lung cancer.

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.

E. Winer, G. Hortobagyi, K. Blackwell, 2019 .

A phase I study of irinotecan as a 3-week schedule in children with refractory or recurrent solid tumors.

D. Frappaz, G. Vassal, F. Doz, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Durvalumab activity in previously treated patients who stopped durvalumab without disease progression

J. Soria, A. Gupta, Pablo Martinez, 2019, Journal for ImmunoTherapy of Cancer.

Discovery and development of novel therapies in advanced breast cancer: rapid development of ribociclib

G. Caponigro, S. Scherer, C. Germa, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.

L. Chow, A. Bardia, N. Harbeck, 2018, The Lancet. Oncology.

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer

E. Winer, G. Hortobagyi, K. Blackwell, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.

E. Winer, G. Hortobagyi, K. Blackwell, 2016, The New England journal of medicine.

PI3K inhibitors as new cancer therapeutics: implications for clinical trial design

E. di Tomaso, P. Aimone, C. Massacesi, 2016, OncoTargets and therapy.

A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer.

Sung-Bae Kim, C. Geyer, J. Bonneterre, 2013, European journal of cancer.

Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patients.

J. Pierga, Y. Bécouarn, J. Raoul, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract GS2-05: First-line ribociclib vs placebo with goserelin and tamoxifen or a non-steroidal aromatase inhibitor in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: Results from the randomized phase III MONALEESA-7 trial

A. Bardia, N. Harbeck, D. Tripathy, 2018 .

Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 trial

G. Hortobagyi, D. Cameron, L. Hart, 2017, Breast Cancer Research and Treatment.

16OFirst-line ribociclib + letrozole in HR+, HER2– ABC: Efficacy by baseline tumor markers

F. André, M. Campone, E. Alba, 2017 .

S5-7: A Phase 2, Randomized, Open-Label, Study of Neratinib (HKI-272) vs Lapatinib Plus Capecitabine for 2nd/3rd-Line Treatment of HER2+ Locally Advanced or Metastatic Breast Cancer.

C. Geyer, J. Bonneterre, J. Vermette, 2011 .

Long-duration, weekly treatment with gemcitabine plus vinorelbine for non-small cell lung cancer: a multicenter phase II study.

B. Milleron, E. Quoix, A. Depierre, 2006, Lung cancer.

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer

E. Winer, G. Hortobagyi, K. Blackwell, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial

S. Verma, M. Campone, L. Hart, 2017, Breast Cancer Research and Treatment.

Abstract PD4-06: First-line ribociclib + letrozole in hormone receptor-positive, HER2-negative advanced breast cancer: Efficacy by baseline circulating tumor DNA alterations in MONALEESA-2

G. Hortobagyi, M. Campone, L. Hart, 2018 .

Ribociclib + letrozole for first-line treatment of HR+, HER2− ABC: efficacy, safety, and pharmacokinetics

G. Hortobagyi, F. André, M. Campone, 2016 .

Abstract P4-22-16: First-line ribociclib + letrozole in patients with HR+, HER2– advanced breast cancer (ABC) presenting with visceral metastases or bone-only disease: A subgroup analysis of the MONALEESA-2 trial

E. Winer, M. Campone, H. Burris, 2017 .

Abstract P4-22-18: Phase Ib safety, efficacy, and molecular analysis of ribociclib (LEE011) plus letrozole for the treatment of ER+, HER2– advanced breast cancer

D. Juric, A. Wardley, P. Munster, 2017 .

A phase I food-effect study of the ribociclib (LEE011) drug-in-capsule (DiC) formulation in healthy subjects.

C. Germa, S. Dhuria, Ravi K. Siddani, 2015 .

Ph III randomized studies of the oral pan-PI3K inhibitor buparlisib (BKM120) with fulvestrant in postmenopausal women with HR+/HER2– locally advanced or metastatic breast cancer (BC) after aromatase inhibitor (AI; BELLE-2) or AI and mTOR inhibitor (BELLE-3) treatment.

P. Lønning, J. Baselga, H. Iwata, 2013 .

Abstract OT2-3-09: Phase III randomized study of the oral pan-PI3K inhibitor BKM120 with fulvestrant in postmenopausal women with HR+/HER2– locally advanced or metastatic breast cancer resistant to aromatase inhibitor – BELLE-2

J. Baselga, H. Iwata, W. Jonat, 2012 .

Abstract CT045: Ribociclib + letrozole for first-line treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): efficacy by baseline tumor markers

G. Hortobagyi, F. André, M. Campone, 2017 .

Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib + letrozole in hormone receptor-positive (HR+), HER2-negative (HER2–), advanced breast cancer (ABC).

E. Winer, G. Hortobagyi, K. Blackwell, 2017 .

Efficacy and safety of ribociclib (LEE011) + letrozole in elderly patients with hormone receptor-positive (HR+), HER2-negative (HER2−) advanced breast cancer (ABC) in MONALEESA-2

M. Campone, L. Hart, H. Burris, 2017 .

A View on Drug Development for Cancer Prevention.

J. Hadfield, G. Schiavon, Z. Szucs, 2023, Cancer discovery.